Un análisis desde la perspectiva del sector de la salud en América Latina y el Caribe
Washington, D.C., 2017
Guide pour les pays à faibles revenus.
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
Doc. No.: INS/GDL/001-(Annexes)
Supplement article
The Journal of Infectious Diseases® 2017;216(S7):S675–8
DOI: 10.1093/infdis/jix368
Finding the Missing Tuberculosis Patients • JID 2017:216 (Suppl 7) • S675
Downloaded from https://academic.oup.com/jid/article-abstract/216/suppl_7/S675/4595547
by guest on 13 Nove...mber 2017
more
WHO Progress Brief
Progress Brief
July 2017
PQDx 0027-012-00 WHO
PQDx Public Report
May/2017, version 4.0
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.12
Establishing trauma referral pathways to provide urgent life-saving assistance for displaced populations and civilians remaining in Ar-Raqqa.
In July 2017, a WHO team comprising an external trauma care specialist and two WHO staff members visited the governorates of Ar-Raqqa and neighbouring Al-Ha...sakeh to assess the situation
more
Le paludisme, appelé également malaria, ou « Mal‘aria », ce qui signifie « mauvais air
», est une maladie qui menace 3 milliards de personnes dans 99 pays dans le monde.1
Les personnes les plus vulnérables sont les jeunes enfants et les femmes enceintes,
car c’est parmi cette populatio...n que le risque de décès est le plus élevé.2
Au Bénin, le paludisme représente environ 41% des motifs de recours aux soins et
première cause de consultation, d’hospitalisation et de décès parmi la population en 2012
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more